Replies to post #159032 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I was briefly concerned about the publication, because after the ASM I read LL stepped down as editor of the Journal of Neurooncology. My concern immediately dissipated when I found out she stepped aside last year, before the ASM. Now, I rank that Journal most likely, as it is the highest impact journal for neurooncology. I rank ASCO’s Journal of Clinical Oncology second most likely for a number of reasons. These are just my opinions.

[VuBru]

To those of you concerned about the publication - the fact that it has not appeared yet, or may not appear even in the next couple of weeks, has no bearing on its' quality or its' eventual publication status. I publish for a living, and can tell you it is often a long and painful process (but worth the wait). Reading between the lines of what was said at the ASM, I think they are at least at the stage where they have submitted revisions and are awaiting a response from the journal reviewers as to whether the initial reviewer concerns have been adequately addressed. They might get it accepted as is, or might have to go through another round of revisions. Then it has to be sent to the publisher, galley proofs edited, etc. It could come out tomorrow or it could be April or May, but it's definitely coming. If they did not get a positive response from the journal initially, I see no reason for the delay of the ASM, especially since there were no votes on any key issues that took place. Clearly, the company is as irritated as the rest of us at how long it is taking, but that is how the sausage gets made ;-)